Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Current Taxes (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Current Taxes for 10 consecutive years, with $41.6 million as the latest value for Q4 2025.

  • Quarterly Current Taxes rose 60.53% to $41.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $41.6 million through Dec 2025, up 60.53% year-over-year, with the annual reading at $41.6 million for FY2025, 60.53% up from the prior year.
  • Current Taxes for Q4 2025 was $41.6 million at BeOne Medicines, up from $11.2 million in the prior quarter.
  • The five-year high for Current Taxes was $41.6 million in Q4 2025, with the low at $5.3 million in Q2 2024.
  • Average Current Taxes over 5 years is $22.3 million, with a median of $22.0 million recorded in 2021.
  • The sharpest move saw Current Taxes surged 125.85% in 2021, then crashed 69.09% in 2024.
  • Over 5 years, Current Taxes stood at $21.4 million in 2021, then rose by 17.73% to $25.2 million in 2022, then fell by 8.88% to $23.0 million in 2023, then increased by 12.98% to $25.9 million in 2024, then skyrocketed by 60.53% to $41.6 million in 2025.
  • According to Business Quant data, Current Taxes over the past three periods came in at $41.6 million, $11.2 million, and $5.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.